Skip to main content
. 2020 Jul 30;79(10):1286–1289. doi: 10.1136/annrheumdis-2020-217712

Table 1.

Comparison of baseline demographic, clinical and laboratory features between patients treated with colchicine plus (+) standard-of-care (SoC) or with SoC only

Clinical features Colchicine
+
SoC, n=122
SoC, n=140 P value
Male (%) 77 (63) 90 (64) 0.84
Age (years), mean (SD) 69.3 (9.6) 70.5 (13.8) 0.12
Period of observation (days), mean (SD) 21.3 (6.8) 25.0 (14.8) 0.012
Smokers or previous smokers (%) 21/96 (22) 18/113 (16) 0.37
Cardiovascular comorbidities* (%) 65/101 (64) 85/115 (74) 0.22
Chronic obstructive bronchopneumonia (%) 17/103 (17) 24/111 (22) 0.34
History of malignanicies (%) 9/104 (9) 24/116 (21) 0.013
Ever treated with hydroxychloroquine (%) 46/102 (45) 78/138 (57) 0.08
Ever treated with lopinavir/ritonavir (%) 10/106 (9) 53/139 (38) <0.0001
Ever treated with dexamethasone (%) 62/107 (58) 44/139 (32) <0.0001
PaO2/FiO2 (mm Hg/%), mean (SD) 176.6 (81) 244.9 (106) <0.0001
Ferritin (ng/mL), mean (SD) 1987 (1983) 1130 (1104) 0.0005
C reactive protein (mg/L), mean (SD) 159.0 (92.9) 112.5 (82.6) 0.0003
Neutrophil count (cell/µL), mean (SD) 6859 (4070) 5844 (3786) 0.022
Lymphocyte count (cell/µL), mean (SD) 921 (427) 1016 (660) 0.75

*Cardiovascular comorbidities: any history of cardiovascular disease, including coronary heart disease (ie, myocardial infarction, angina and coronary revascularisation), cerebrovascular disease (ie, stroke and transient ischaemic attack) and/or peripheral arterial disease, diabetes mellitus and arterial hypertension.